Roche aban­dons an­ti-myo­statin ap­proach to Duchenne MD — one more nail in the class' cof­fin

6 years ago
R&D

Some bat­tle test­ed neu­ro­science vets are go­ing all out on ear­ly on­set de­men­tia — with a $44M launch round to build ...

6 years ago
Startups
R&D

HHS is tak­ing Gilead to court, seek­ing dam­ages for in­fring­ing gov­ern­ment HIV patents

6 years ago
Pharma
FDA+

Te­va spin­out de­lays NASH IPO while Galera prices be­low range

6 years ago
Financing

Re­genxBio runs in­to par­tial hold for an­ti-VEGF gene ther­a­py as FDA in­ves­ti­gates de­liv­ery de­vice

6 years ago
Cell/Gene Tx
FDA+

FDA re­names and re­struc­tures on­col­o­gy of­fice

6 years ago
FDA+

George Church start­up eGe­n­e­sis rakes $100M to ramp up CRISPR pig or­gan trans­plants

6 years ago
Financing

Bio­gen dou­bles down on biosim­i­lars pact with Sam­sung Bioepis, bag­ging oph­thal­mol­o­gy, an­ti-TNF drugs

6 years ago
Deals

Re­gen­eron plans $1B stock buy­back; Mer­ck part­ner touts PhI­Ib re­sults for Keytru­da com­bo in pan­cre­at­ic can­cer

6 years ago
News Briefing

Alzheimer's break­through? Not so fast — ex­perts poke holes in da­ta un­der­ly­ing Chi­na's sur­prise ap­proval

6 years ago
China
In Focus

New Am­pli­tude fund looks to bet over $100 mil­lion on in­cip­i­ent Cana­di­an biotech mar­ket

6 years ago
Financing

Ear­ly da­ta on NextCure's im­muno-on­col­o­gy drug in lung can­cer pa­tients de­lights in­vestors

6 years ago
R&D

Evotec and Vi­for launch joint kid­ney dis­ease ven­ture

6 years ago
Deals

As­traZeneca sketch­es plans for a $1B ven­ture fund — and it's go­ing to Chi­na

6 years ago
Financing
China

Tardy mar­ket­ing ap­pli­ca­tion fil­ing, tri­al fail­ure trou­ble Su­per­nus in­vestors

6 years ago
R&D

Eli Lil­ly, Boehringer In­gel­heim re­vise pro­lif­ic di­a­betes pact, fir­ing all cylin­ders for block­buster Jar­diance ...

6 years ago
Deals

On the heels of a $6.9B As­traZeneca pact, IP dis­pute be­tween Dai­ichi Sankyo and Seat­tle Ge­net­ics rips open in law­suit

6 years ago
R&D
Pharma

Steve Kaf­ka joins Sec­tion 32 as man­ag­ing part­ner; Take­da auc­tions off $660M drug port­fo­lio in bid to re­duce ...

6 years ago
News Briefing

An­oth­er ex-Shire re­search ex­ec heads out, grab­bing top R&D job at deal-hun­gry Ipsen as post-buy­out ex­o­dus con­tin­ues

6 years ago
People
R&D

Andy Plump teams with MD An­der­son on the race to cell ther­a­py 2.0 — and they’re al­ready plan­ning a piv­otal

6 years ago
Deals
R&D

It took a 3-year strug­gle, but No­var­tis fi­nal­ly gets a green light on their copy­cat to Am­gen's big block­buster

6 years ago
R&D

Unum drops an­oth­er pro­gram for trou­bled PhI ther­a­py, mov­ing its eggs to the sol­id tu­mor bas­ket

6 years ago
R&D

As CRISPR hori­zons cloud, a start­up fo­cus­es on the next big thing with pow­er­house po­ten­tial — the RNA edit­ing ...

6 years ago
Startups

Is FDA do­ing enough to bring biosim­i­lars to mar­ket? Ex­perts dis­cuss

6 years ago
Pharma
FDA+
First page Previous page 895896897898899900901 Next page Last page
A service from the Financial Times